Tiny RNA clues may explain bone disease differences
NCT ID NCT03838991
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
Fibrous dysplasia is a rare bone disease that causes pain, fractures, and deformities, but its severity varies widely for unknown reasons. This study looked at 24 adults—some with the disease and some without—to see if small molecules called microRNAs in blood and bone tissue are linked to how severe the disease is. The goal was to gather knowledge, not to test a treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help explain why fibrous dysplasia affects people differently and point toward new ways to monitor or treat the disease.
- What could go wrong
- This is a small, observational study that does not test any treatment. It may not find clear links between microRNAs and disease severity, and any findings will need much more research to be useful.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
24 people
The number who actually took part.
- Started
-
Jan 2019
- Finished
-
Mar 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Control population : * men and women, * 18 years-old and over, * consulting a rheumatologist or an orthopedist for arthrosis * have scheduled surgery for hip or knee replacement surgery or any intervention involving the lower limb or upper limb. Patients with Fibrous dysplasia: * men and women, * 18 years-old and over, * with a diagnosis of fibrous dysplasia previously established by a rheumatologist. Exclusion Criteria: * Refusal to participate in the study * Long- term corticosteroids treatment (\> 3 months) * Treated osteoporosis * Chronic inflammatory rheumatism (rheumatoid arthritis, psoriasic arthritis, spondyloarthropathy) * Collagen disease (osteogenesis imperfecta…) * Paget's disease, benign bone tumors * Uncontrolled hypo/hyper-thyroidism, hypo/hyper-parathryoidism * Severe renal impairment (GFR \< 30 ml/min/1.73m2) * Cancer or bone metastases (current or in the past two years) * Paget disease, benign bone tumor (osteoid osteoma, enchondroma …) * Malabsorptive disease (Celiac disease, Whipple's disease, intestinal bypass, short bowel syndrome) and inflammatory bowel disease * Pregnant women or lactating * Psychiatric disorders * Difficulty in understanding French * Not a beneficiary of french social security * Patients protected by law
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fibrous dysplasia of bone are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Rhumatologie & INSERM U1033, Pavillon F, Hopital Edouard Herriot
Lyon, 69437, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.